Company: SCLXW
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0000950170-25-006774
Chunk: 11

Company: Scilex Holding Co
Filing Date: 2025-01-17
Form: 424B3
Chunk 11
---
 |   |
| Conversion of Convertible Debentures into common stock                                                                          | $                               |       — |   |     | $    |   7,735 |   |
| Right-of-use assets obtained in exchange for operating lease liabilities with lease modification                                | $                               |       — |   |     | $    |   2,523 |   |
| Oramed Note issuance at fair value                                                                                              | $                               |       — |   |     | $    | 106,252 |   |
| Other non-cash consideration in connection with share repurchase                                                                | $                               |       — |   |     | $    |  26,154 |   |
| Excise tax in connection with share repurchase included in accrued expenses                                                     | $                               |       — |   |     | $    |   1,375 |   |

See accompanying notes to unaudited condensed consolidated financial statements

<div align='center'>5

SCILEX HOLDING COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)</div>

1. Nature of Operations and Basis of Presentation

Organization and Principal Activities

Scilex Holding Company (“Scilex” and together with its wholly owned subsidiaries, the “Company”) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has five wholly owned subsidiaries: Scilex Inc. (“Legacy Scilex”), Scilex Pharmaceuticals Inc. (“Scilex Pharma”), Semnur Pharmaceuticals, Inc. (“Semnur”), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC. The business combination with Vickers (the “Business Combination”) closed in November 2022.

The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (“ZTlido”), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. In June 2022, the Company in-licensed the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution (“GLOPERBA”), a U.S. Food and Drug Administration (“FDA”)-approved prophylactic treatment